Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Recruiting now Phase 3 NCT06252649
Run by Amgen · for 18 and older · All sexes
What this study is about
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Who can join (things the study team will check)
✅ You may be able to join if…
- Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.
- Central laboratory detection of KRAS p.G12C mutation.
- Measurable metastatic disease per RECIST v1.1 criteria.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.
- Adequate organ function.
🚫 You may not be able to join if…
- Active, untreated brain metastases.
- Leptomeningeal disease
- Previous treatment with a KRAS p.G12C inhibitor
- History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan
Where this trial is running
- Ironwood Cancer and Research Centers Scottsdale, Chandler, Arizona, United States
- Providence Saint Jude Medical Center, Fullerton, California, United States
- City of Hope National Medical Center, Long Beach, California, United States
- Cancer and Blood Research Center, LLC, Los Alamitos, California, United States
- California Research Institute, Los Angeles, California, United States
- Norwalk Hospital, Norwalk, Connecticut, United States
- Cancer Specialists of North Florida - Southpoint, Jacksonville, Florida, United States
- D and H Cancer Research Center, Margate, Florida, United States
- Mid Florida Hematology and Oncology Centers PA, Orange City, Florida, United States
- Boca Raton Clinical Research Medical Center Inc, Plantation, Florida, United States
- Georgia Cancer Specialists, Atlanta, Georgia, United States
- Insight Research Institute, Chicago, Illinois, United States
+ 280 more sites.
Who to contact
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06252649.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.